SI4027976T1 - Sestavki rifabutina in postopek izdelave - Google Patents

Sestavki rifabutina in postopek izdelave

Info

Publication number
SI4027976T1
SI4027976T1 SI202030697T SI202030697T SI4027976T1 SI 4027976 T1 SI4027976 T1 SI 4027976T1 SI 202030697 T SI202030697 T SI 202030697T SI 202030697 T SI202030697 T SI 202030697T SI 4027976 T1 SI4027976 T1 SI 4027976T1
Authority
SI
Slovenia
Prior art keywords
rifabutin
compositions
making
rifabutin compositions
Prior art date
Application number
SI202030697T
Other languages
English (en)
Slovenian (sl)
Inventor
Sergio Lociuro
Stefano Biondi
Glenn E. Dale
Marilyne Bourotte
Marc Gitzinger
Original Assignee
BioVersys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioVersys AG filed Critical BioVersys AG
Publication of SI4027976T1 publication Critical patent/SI4027976T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI202030697T 2019-09-12 2020-08-03 Sestavki rifabutina in postopek izdelave SI4027976T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US201962941160P 2019-11-27 2019-11-27
EP20768379.8A EP4027976B1 (en) 2019-09-12 2020-08-03 Rifabutin compositions and method of making
PCT/IB2020/000648 WO2021048612A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Publications (1)

Publication Number Publication Date
SI4027976T1 true SI4027976T1 (sl) 2026-02-27

Family

ID=72428294

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202030697T SI4027976T1 (sl) 2019-09-12 2020-08-03 Sestavki rifabutina in postopek izdelave

Country Status (23)

Country Link
US (1) US12370184B2 (cg-RX-API-DMAC7.html)
EP (2) EP4027976B1 (cg-RX-API-DMAC7.html)
JP (2) JP7777518B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220103697A (cg-RX-API-DMAC7.html)
CN (4) CN113015519B (cg-RX-API-DMAC7.html)
AU (2) AU2020346414B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004659A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154318A1 (cg-RX-API-DMAC7.html)
DK (1) DK4027976T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056897T3 (cg-RX-API-DMAC7.html)
FI (1) FI4027976T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251645T1 (cg-RX-API-DMAC7.html)
LT (1) LT4027976T (cg-RX-API-DMAC7.html)
MX (1) MX2022003075A (cg-RX-API-DMAC7.html)
MY (1) MY210244A (cg-RX-API-DMAC7.html)
PH (1) PH12022550606A1 (cg-RX-API-DMAC7.html)
PL (1) PL4027976T3 (cg-RX-API-DMAC7.html)
PT (1) PT4027976T (cg-RX-API-DMAC7.html)
RS (1) RS67627B1 (cg-RX-API-DMAC7.html)
SI (1) SI4027976T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500491T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048612A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202203357B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies
WO2026022215A1 (en) * 2024-07-23 2026-01-29 BioVersys AG Lyophilized formulations of rifabutin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN1775214A (zh) * 2005-11-18 2006-05-24 武汉大学 利福喷丁、利福平、利福布丁或利福定注射剂及其制备方法
CA2641064C (en) * 2006-03-23 2017-03-07 Agriculture Victoria Services Pty Limited Antimicrobial protein
CN101362067A (zh) 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
WO2012106364A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) * 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
WO2015104668A2 (en) 2014-01-09 2015-07-16 Camus Pharma Pvt. Ltd. Lyophilized formulations for parenteral use
WO2016014437A1 (en) 2014-07-21 2016-01-28 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
CA3055311A1 (en) 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
AU2025283482A1 (en) 2026-01-15
RS67627B1 (sr) 2026-02-27
CN120267667A (zh) 2025-07-08
CA3154318A1 (en) 2021-03-18
WO2021048612A1 (en) 2021-03-18
MY210244A (en) 2025-09-04
CN113015519A (zh) 2021-06-22
PL4027976T3 (pl) 2026-02-16
US20240000759A1 (en) 2024-01-04
SMT202500491T1 (it) 2026-03-09
KR20220103697A (ko) 2022-07-22
FI4027976T3 (fi) 2025-12-12
DK4027976T3 (da) 2025-12-22
CN113015519B (zh) 2025-03-28
PT4027976T (pt) 2025-12-23
US12370184B2 (en) 2025-07-29
CN120267666A (zh) 2025-07-08
JP7777518B2 (ja) 2025-11-28
ES3056897T3 (en) 2026-02-25
PH12022550606A1 (en) 2023-01-23
EP4027976B1 (en) 2025-10-01
JP2022548858A (ja) 2022-11-22
JP2026027477A (ja) 2026-02-18
CN120267668A (zh) 2025-07-08
HRP20251645T1 (hr) 2026-02-13
ZA202203357B (en) 2023-12-20
EP4748371A1 (en) 2026-05-27
LT4027976T (lt) 2026-01-12
EP4027976A1 (en) 2022-07-20
BR112022004659A2 (pt) 2022-06-21
MX2022003075A (es) 2022-07-11
AU2020346414B2 (en) 2025-10-02
AU2020346414A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
GB2597163B (en) Cannabinoid compositions and methods of using
IL278978A (en) Preparations and methods for treating eczema
IL276135A (en) Preparations and methods of use
ZA202004531B (en) Compositions containing thymohydroquinone and their method of preparation
ZA202100780B (en) Bismuth-thiol compositions and methods of use
PT3773750T (pt) Formulação e método de preparação
GB201717885D0 (en) Prothesis and method of manufacture
SG10202011799RA (en) Resist composition and method of forming resist pattern
SMT202500491T1 (it) Composizioni di rifabutina e metodo di realizzazione
SG10201910703QA (en) Resist composition and method of forming resist pattern
IL288415A (en) Combinations and methods for the treatment of hemochromatosis
IL286704A (en) Probiotic biofilm preparations and methods for their preparation
SG10202008014RA (en) Resist composition and method of forming resist pattern
PL4010269T3 (pl) Kompozycja do natryskiwania i metoda
HUE069670T2 (hu) Készítmény és módszer a sclerosis multiplex kezelésére
ZA202000609B (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
GB201810923D0 (en) Compositions and method of treatment
SG11202012283XA (en) Additive composition and method of preparing the same
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201919385D0 (en) Compositions and methods of manufacture
IL288495A (en) Compounds and methods of making ribitol
GB2599284B (en) Edible paste and composition and method of preparation
GB201913124D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201807964D0 (en) Multi-pack and method of making multi-pack